New Launch1 Apr 2025, 06:21 pm
Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India
AI Summary
Emcutix Biopharmaceuticals Limited, a subsidiary of Emcure Pharmaceuticals Limited, announced an exclusive in-licensing agreement with WiQo, an innovative Italian derma-cosmetic and medical device company. The partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's ground-breaking product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region. PRX-PLUS is an innovative combination that promotes immediate skin lifting without the use of injections, recovery time, or discomfort. It is safe for all skin types and phototypes and suitable for use in all seasons.
Key Highlights
- Emcutix secures exclusive rights for the Indian market to import, promote and distribute PRX-PLUS, WiQo’s topical painless booster for skin tightening
- PRX-PLUS is an innovative combination that promotes immediate skin lifting without the use of injections, recovery time, or discomfort
- PRX-PLUS is safe for all skin types and phototypes and suitable for use in all seasons
- The dermatology market in India has been seeing consistent and significant growth, with a potential growth rate of 11-12% in the near future
- Emcutix Biopharmaceuticals Limited is committed to delivering innovative skincare and aesthetic solutions in India